FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
Intraprostatic drug elution therapy shows promise for BPH-related LUTS
ASCO 2025: What to watch for in GU oncology
Subcutaneous nivolumab approved in EU, Canada for solid tumors